PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ahead of its fiscal Q4 2025 earnings, expected to be released on February 24, 2026. The Street expects the company to post quarterly revenue of around $372.87 million and a GAAP EPS of $1.56.
Recently, on January 26, Ryan Zimmerman from BTIG maintained a Hold rating on the stock without disclosing any price targets. Earlier on December 18, Richard Newitter from Truist Financial reiterated a Buy rating on the stock, but lowered the price target from $50 to $47.
Analysts at Truist noted that they remain optimistic on the MedTech sector in 2026, mainly due to its attractive valuation compared to other healthcare areas. However, the price target reduction reflects the concern that the sector could become a source rather than the destination of new healthcare investments. The firm also highlighted that they prefer companies in the MedTech sector which present catalysts for durable growth in 2026.
That said, Wall Street’s 12-month average price target reflects more than 77% upside from the current levels and 79% of the 14 analysts covering the stock maintain a Buy rating on PROCEPT BioRobotics Corporation (NASDAQ:PRCT).
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage company specializing in surgical robotics solutions for urology. The AquaBeam Robotic System is the company’s flagship product with an advanced image-guided system designed for minimally-invasive urologic surgeries.
While we acknowledge the potential of PRCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.